*Lupin* has signed exclusive distribution pact with Fordoz Pharma for granting the company, exclusive rights to market and distribute two complex injectable assets which are in advanced stages of development in the U.S. and its territories. The two assets are in the oncology and anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals.
Impact: Positive